HO WAH GENTING BERHAD’S JOINT VENTURE PARTNER SUBMITTED SECOND RESPONSE TO UNITED STATES FOOD AND DRUG ADMINISTRATION’S INQUIRIES IN RELATION TO COVID-19 VACCINE PREVENTION
KUALA LUMPUR, 05 OCTOBER 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) joint venture partner, US-based E-Mo Biology Inc (“EBI”), expects a response from United States Food and Drug Administration (“FDA”) within 30 days from the date of FDA’s receipt of EBI’s second reply to FDA’s request to provide further information on the Investigational New Drug (“IND”) application which repurposes the use of existing poliomyelitis virus vaccines (“PVV”) for prevention of COVID-19.
The main objective of the IND application is to assess the cross-reactivity between the PVV-induced antibodies and SARS-CoV-2 and evaluate the effectiveness of oral polio vaccine (“OPV”) as a preventive protection against COVID-19.
In August, the FDA has provided its second communication to EBI, requesting further information on the IND application to use PVV for prevention of COVID-19.
To recap, HWGB's wholly-owned subsidiary, HWGB Biotech Sdn Bhd, signed a joint-venture agreement with EBI for the research and development of vaccines, immunological treatment and diagnostic product development in relation to the SARS-CoV-2.
HWGB Chief Executive Officer, Dato’ Aaron Lim said EBI is optimistic with its second reply to the FDA, which reaffirms the company’s progress and commitment in the research and discovery of a vaccine for COVID-19.
"The progress with EBI and FDA affirms our position and approach as a leading company for the research and development of a preventive vaccine for COVID-19.”
"We look forward to getting FDA’s approval through the collaborations with our partners and we again want to emphasise that time is important in the production of the vaccine given how the pandemic has ravaged global population and weigh on economy," Dato’ Aaron Lim said.
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wire and cable and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wire and cable; and travel agent and tour related services.
For more information about HWGB Biotech, please visit https://hwgbbiotech.com/ and/or https://www.facebook.com/hwgbbiotech Please also feel free to subscribe to our newsletter online to get latest exciting developments of our new ventures. Click on http://subscription.hwgbbiotech.com to subscribe.
ABOUT E-MO BIOLOGY INC.
E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to prevent COVID-19 SARS-COV-2 infection and severity.
EBI is founded by Prof. Xie QiYi, who serves as Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on quality, regulatory and clinical affairs for quality systems.